Showing results (11-20 of 19) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Expert Review of Vaccines|February 22, 2011
Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccinesLinda C Benavides, Alan K Sears, Jeremy D Gates, et al.Cancer|October 13, 2011
Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Elizabeth A Mittendorf, Guy T Clifton, Jarrod P Holmes, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2009
The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02Linda C Benavides, Jeremy D Gates, Mark G Carmichael, et al.Journal of the American College of Surgeons|February 21, 2009
Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patientsJeremy D Gates, Mark G Carmichael, Linda C Benavides, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2008
Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccineJarrod P Holmes, Linda C Benavides, Jeremy D Gates, et al.Cancer Immunology, Immunotherapy : CII|April 9, 2008
Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Asna Amin, Linda C Benavides, Jarrod P Holmes, et al.Vaccine|September 23, 2010
Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptideJeremy D Gates, Guy T Clifton, Linda C Benavides, et al.Expert Opinion on Biological Therapy|September 8, 2011
AE37: a novel T-cell-eliciting vaccine for breast cancerAlan K Sears, Sonia A Perez, Guy T Clifton, et al.The Journal of Trauma and Acute Care Surgery|May 31, 2023
Committee on Surgical Combat Casualty Care position statement: Neurosurgical capability for the optimal management of traumatic brain injury during deployed operationsJennifer M Gurney, Matthew D Tadlock, Bradley A Dengler, et al.Pageof 2